Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Achillion Pharmaceuticals

Related ACHN
Achillion Announces Janssen Initiated Phase 2a Study to Evaluate Combination of AL-335, ACH-3102, and Simeprevir for Treatment of Genotype 1 Chronic HCV
UBS: Biotech Will Continue To Outperform In 2015

In a report published Friday, Piper Jaffray & Co. reiterated its Overweight rating on Achillion Pharmaceuticals (NASDAQ: ACHN), but slightly lowered its price target from $17.00 to $16.00.

Piper Jaffray noted, “Achillion ended 2Q:12 with cash of $60 million and received gross proceeds of $41.8 million by issuing QVT 6.367 million shares at $6.57. Achillion has begun dosing HCV genotype 1 patients with NS5A inhibitor ACH-3102 with data in 3Q:12. We expect Achillion to begin Phase II combo trials with protease inhibitor sovaprevir by year-end with data in early 2013. Recent set-backs with Bristol-Myers' and Idenix's ‘nucs' benefit Achillion. We expect the wave of consolidation in HCV will continue with Achillion a likely target. We reiterate our Overweight rating and are trimming our target to $16 from $17 to account for dilution from the QVT deal.”

Achillion Pharmaceuticals closed on Thursday at $6.57.

Latest Ratings for ACHN

Oct 2015JefferiesMaintainsHold
Sep 2015JefferiesInitiates Coverage onHold
Sep 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings


Related Articles (ACHN)

Get Benzinga's Newsletters